Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Ayana Pharma
Ayana Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Doxorubicin
Doxorubicin
2021-10-12
Myeloid leukemia acute
,
Breast neoplasms
,
Ovarian neoplasms
,
Thyroid neoplasms
,
Gastrointestinal neoplasms
,
Lung neoplasms
,
Multiple myeloma
,
Neuroblastoma
,
Precursor cell lymphoblastic leukemia-lymphoma
,
Urinary bladder neoplasms
,
Osteosarcoma
,
Hodgkin disease
,
Soft tissue neoplasms
,
Kaposi sarcoma
,
Wilms tumor
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Doxorubicin
ovarian neoplasms
,
ovarian epithelial carcinoma
Doxorubicin hydrochloride
ovarian neoplasms
,
ovarian epithelial carcinoma
Caelyx
ovarian neoplasms
,
ovarian epithelial carcinoma
Doxorubin
ovarian neoplasms
,
ovarian epithelial carcinoma
Hydroxydaunomycin
ovarian neoplasms
,
ovarian epithelial carcinoma
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use